Hsu CH - Search Results

1

Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.

Hsu CH, Weng PW, Chen MY, Yeh CT, Setiawan SA, Yadav VK, Wu ATH, Tzeng DTW, Gong JX, Yang Z, Tzeng YM. Hsu CH, et al. Chem Biol Interact. 2023 Jan 25;370:110329. doi: 10.1016/j.cbi.2022.110329. Epub 2022 Dec 22. Chem Biol Interact. 2023. PMID: 36565974

2

Role of GDF15/MAPK14 Axis in Chondrocyte Senescence as a Novel Senomorphic Agent in Osteoarthritis.

Weng PW, Pikatan NW, Setiawan SA, Yadav VK, Fong IH, Hsu CH, Yeh CT, Lee WH. Weng PW, et al. Among authors: hsu ch. Int J Mol Sci. 2022 Jun 24;23(13):7043. doi: 10.3390/ijms23137043. Int J Mol Sci. 2022. PMID: 35806043 Free PMC article.

3

Targeting the SREBP-1/Hsa-Mir-497/SCAP/FASN Oncometabolic Axis Inhibits the Cancer Stem-like and Chemoresistant Phenotype of Non-Small Cell Lung Carcinoma Cells.

Tiong TY, Weng PW, Wang CH, Setiawan SA, Yadav VK, Pikatan NW, Fong IH, Yeh CT, Hsu CH, Kuo KT. Tiong TY, et al. Among authors: hsu ch. Int J Mol Sci. 2022 Jun 30;23(13):7283. doi: 10.3390/ijms23137283. Int J Mol Sci. 2022. PMID: 35806291 Free PMC article.

4

Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.

Chen MY, Hsu CH, Setiawan SA, Tzeng DTW, Ma HP, Ong JR, Chu YC, Hsieh MS, Wu ATH, Tzeng YM, Yeh CT. Chen MY, et al. Among authors: hsu ch. Phytomedicine. 2023 Jan;108:154478. doi: 10.1016/j.phymed.2022.154478. Epub 2022 Sep 25. Phytomedicine. 2023. PMID: 36265255

5

Cancer-Associated Exosomal CBFB Facilitates the Aggressive Phenotype, Evasion of Oxidative Stress, and Preferential Predisposition to Bone Prometastatic Factor of Breast Cancer Progression.

Hsu CH, Ma HP, Ong JR, Hsieh MS, Yadav VK, Yeh CT, Chao TY, Lee WH, Huang WC, Kuo KT, Fong IH, Lin CC, Su CM. Hsu CH, et al. Dis Markers. 2022 Jul 19;2022:8446629. doi: 10.1155/2022/8446629. eCollection 2022. Dis Markers. 2022. PMID: 35903297 Free PMC article.

6

Risk Values of Weight and Body Mass Index for Chest Wall Thickness in Patients Requiring Needle Thoracostomy Decompression.

Hsu CH, Lin TY, Ou JC, Ong JR, Ma HP. Hsu CH, et al. Emerg Med Int. 2020 Oct 26;2020:2070157. doi: 10.1155/2020/2070157. eCollection 2020. Emerg Med Int. 2020. PMID: 33178460 Free PMC article.

7

Release of lead, copper, zinc from the initial corrosion of brass water meter in drinking water: Influences of solution composition and electrochemical characterization.

Hsu CH, Ng DQ, Lin YP. Hsu CH, et al. Environ Pollut. 2024 May 13;352:124154. doi: 10.1016/j.envpol.2024.124154. Online ahead of print. Environ Pollut. 2024. PMID: 38750810

8

Prehospital Ground and Helicopter-Based Extracorporeal Cardiopulmonary Resuscitation (ECPR) Reduce Barriers to ECPR: A GIS Model.

Gottula AL, Qi M, Lane BH, Shaw CR, Gorder K, Powell E, Danielson K, Ciullo A, Johnson NJ, Tonna JE, Hinckley WR, Koshoffer A, Al-Araji R, Bartos J, Benoit J, Hsu CH; CARES Surveillance Group. Gottula AL, et al. Among authors: hsu ch. Prehosp Emerg Care. 2024 May 13:1-27. doi: 10.1080/10903127.2024.2355652. Online ahead of print. Prehosp Emerg Care. 2024. PMID: 38739864

9

Seagrass repression by green turtles (Chelonia mydas) around Taiping Island in the south China sea: Experimental evidence and management insights.

Hsu CH, Kuo CY, Wei Y, Soong K. Hsu CH, et al. Mar Environ Res. 2024 Apr 7;198:106494. doi: 10.1016/j.marenvres.2024.106494. Online ahead of print. Mar Environ Res. 2024. PMID: 38733738

10

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.

Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Blum Murphy M, Amaya-Chanaga C, Patel A, Hu N, Matsumura Y, Kitagawa Y, Ajani J. Kato K, et al. Among authors: hsu ch. Cancer Med. 2024 May;13(9):e7235. doi: 10.1002/cam4.7235. Cancer Med. 2024. PMID: 38716626 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,314 results

Search Page